Cynbiome® is a preclinical network dedicated to the microbiome and infectious deseases research field which capitalize on the richness and complementarity of players specializing in various fields such as high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, preclinical and clinical activities. Cynbiome® provide a preclinical offer with a core focus on the microbiome field and infectious diseases and pursue R&D activities. The Cynbiome® preclinical network was launched by Cynbiose and is financed by the French government and the Auvergne-Rhône-Alpes region and is supported by Bpifrance.


VirNext is co-founder of the Cynbiome® preclinical network launched by our strategic partner cynbiose. We bring our technologies, virus library, preclinical infectious models and BSL-2/BSL-3 facilities to the @Cynbiome® network. Our objectives are to offer a large preclinical offer with a core focus on the microbiome field and infectious diseases, in order to accelerate and de-risk the development of candidates to meet the major challenges of human health.


Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates in the field of respiratory infectious diseases, from in vitro screening to in vivo efficacy models of infections. 


Cynbiose is the only non-clinical Contract Research Organization (CRO) of its kind in Europe and is AAALAC accredited. The company specializes in the development and commercialization of innovative non-human primate models to accelerate the preclinical development phases of drug candidates. It works on exploratory DMPK and toxicology studies, as well as proof of concept studies in different human pathologies, such as infectious diseases and respiratory conditions, the central nervous system and inflammatory, musculoskeletal disorders and cardiovascular/neurovascular diseases. The company provides its services in line with quality guidelines that meet industry requirements. and is committed in numerous preclinical development programs for new therapies.


VirNext and Cynbiose are in the front line in meeting the ambitions of the French Health 2030 innovation plan and actively contributing to strengthening the positioning of the Auvergne-Rhône-Alpes region and France in the fight against (re)-emerging infectious diseases. We are proud to be able to support academic teams and the biopharmaceutical industry with a very high value-added scientific and technical offer and thus contribute to global health.

Press Release
Press Release_Cynbiose-VirNext.pdf
Adobe Acrobat Document 212.4 KB